TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04602533
Drug: standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiochemotherapy: Cisplatin (75 mg/m² (BSA) D1#) or alternatively Carboplatin (AUC 5 D1) and Etoposide (100 mg/m² (BSA) D1-3) once every 3 weeks for 4-6 cycles and concomitant Radiotherapy (60±6 Gy, 1.8-2 Gy/d or 45±1.5 Gy (1.5 Gy per fraction twice daily, with 4 hours or more between fractions) with start at latest at beginning of cycle 3, ideally during cycle 1) followed by prophylactic cranial irradiation (PCI, if clinically indicated and according to local standard at any time after completion of radio-chemotherapy))~A simultaneous administration of platinum-based chemotherapy (preferred Cisplatin) and radiotherapy for at least 2 cycles should be performed.
Study: NCT02979093
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: All women will receive a nasal spray containing a placebo solution.
Study: NCT02378298
Drug: Iv Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solumedrol is an intravenous glucocorticoid that are the gold standard in TAO. All patients start with 500 mg/weeks for 4 weeks. The response is evaluated and patients are randomised to non-responders or responders. The responders continues with the gold standard treatment that is another 500 mg solumedrol/ week in 2 weeks and then 250 mg/ week in 6 weeks.
Study: NCT02378298
Drug: peroral methylprednisolone and Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Peroral GC (starting with 30 mg and tapering down) is combined with 15-20 mg MTX /week to reduce the needed dose of steroids
Study: NCT01946529
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage and route of administration: Infants \< 1 year 2.5 mg/kg continuous infusion (CI) over 48 hours, days 1-2; participants \> 1 year of age 75 mg/m\^2 CI over 48 hours, days 1-2.
Study: NCT01946529
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosage and route of administration: The dose and route are different in neo-adjuvant/adjuvant chemotherapy and maintenance therapy. Please see the Detailed Description for further information.
Study: NCT01065454
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo three times a day
Study: NCT02525549
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02064010
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, administered orally for 4 weeks
Study: NCT04485585
Drug: BR9006-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Administration to the T/T+M group: 0.2 mg of BR9006-1 will be administered one capsule once a day, five-day repeated-dose
Study: NCT04485585
Drug: BR9006-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Administration to the M group: 50 mg of BR9006-2 will be administered one tablet once a day, eleven-day repeated-dose~* Administration to the T+M group: 50 mg of BR9006-2 will be administered one tablet once a day, five-day repeated-dose
Study: NCT01746979
Drug: Placebo (5 percent dextrose - D5W)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TH-302 placebo (5 percent dextrose - D5W) will be administered as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Study: NCT00352846
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg/m\^2 by vein over 30 Minutes at baseline and 6 months.
Study: NCT01772524
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03883919
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: -Standard of care drug
Study: NCT04313400
Drug: 1.1% w/w AMTX-100 CF-part1
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMTX-100 CF, topical cream with 1.1% w/w active pharmaceutical ingredient
Study: NCT04313400
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cream manufactured to mimic AMTX-100 CF3
Study: NCT04313400
Drug: 1.1% w/w AMTX-100 CF3-part2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMTX-100 CF3, topical cream with 1.1% w/w active pharmaceutical ingredient
Study: NCT02767089
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets similar to Prednisone 2.5 mg and 20 mg were supplied to make the trial doses.
Study: NCT02319616
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded, daily application to one arm for a period of fourteen (14) days
Study: NCT00441142
Drug: ZD6474
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally once a day (at 100 mg/day is the phase II dose; the MTD determined by the phase I portion of the trial) until disease gets worse or participants experience unacceptable side effects
Study: NCT01597765
Drug: curcuminoids, N-acetylcysteine, deferiprone and vitamin E
Approvals — FDA: no, EMA: no, PMDA: no
Description: receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day deferiprone 50 mg/kg/day and vitamin E 400 IU/day
Study: NCT00606034
Drug: U-500 Insulin delivered by Omnipod (disposable insulin pump)
Approvals — FDA: no, EMA: no, PMDA: no
Description: U-500 insulin (concentrated insulin) will be infused continuously subcutaneously using a disposable insulin pump called an Omnipod; the insulin infusion dosage will be individualized to each subject's needs
Study: NCT04630860
Drug: LY03003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine,extended-release microspheres
Study: NCT02138409
Drug: Fentanyl Sublingual Spray (FSS)
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl sublingual spray (FSS) packaged to deliver 100 µg/spray, 200 µg/spray or 400 µg/spray
Study: NCT02138409
Drug: Placebo Sublingual Spray (PSS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sublingual spray (PSS) packaged to match FSS, but deliver no drug
Study: NCT02643563
Drug: Bupivacaine 0.5% + epinephrine 1:200,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% + epinephrine 1:200,000 is used for low-volume ultrasound-guided interscalene brachial plexus block.
Study: NCT02677207
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
Study: NCT05149651
Drug: Totalfill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Totalfill® Bioceramic Root Repair Material -Fast Set Putty is a pre-mixed, bioactive calcium silicate cement which used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy.
Study: NCT01179217
Drug: L-glutamine
Normalized name: L-Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g/kg of L-glutamine will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration. Mixing L-glutamine with soda or highly acidic juices (such as grapefruit juice or lemonade) is not recommended.
Study: NCT01179217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g/kg of placebo (100% maltodextrin) will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration.
Study: NCT00945529
Drug: inhaled nitric oxide (iNO)
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide 40ppm for 48 hours followed by a 6-hour wean.
Study: NCT03633084
Drug: RBM-007 Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: (No additional description)
Study: NCT03094195
Drug: EMA401
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMA401
Study: NCT03094195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02224443
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C , Normal saline infusion will be given with the same infusion volume as group A and B
Study: NCT02224443
Drug: cisatracurium besylate,propofol,remifentanil,sevoflurane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance of anesthesia :Continuous pump infusion 0.05\~0.1mg.kg-1.h-1cisatracurium besylate,4\~8mg.kg-1.h-1propofol,0.1\~0.2μg.kg-1.min-1 remifentanil and sevoflurane inhalation with 0.6%\~1.0%
Study: NCT02034682
Drug: Volulyte 6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: During elective coronary artery bypass grafting surgery, patients need to be attached to a cardiopulmonary bypass circuit. Administration of Volulyte 6% to the cardiopulmonary bypass circuit.
Study: NCT02034682
Drug: Geloplasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: During elective coronary artery bypass grafting surgery, patients need to be attached to a cardiopulmonary bypass circuit. Administration of Geloplasma to the cardiopulmonary bypass circuit.
Study: NCT00729183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets to odanacatib taken orally once weekly for 24 months.
Study: NCT00729183
Drug: Calcium supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplement 500 mg tablet taken orally once daily (up to \~1200 mg total) for 24 months.
Study: NCT00772499
Drug: olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure
Normalized name: amlodipine / hydrochlorothiazide / olmesartan medoxomil Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets and capsules for oral administration once or twice daily for up to 52 weeks
Study: NCT00772499
Drug: atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure
Normalized name: atenolol / chlorthalidone / hydralazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets and capsules for oral administration once or twice daily for up to 52 weeks
Study: NCT02526615
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received either placebo, metformin or rosiglitazone
Study: NCT02260193
Drug: AKB-6548
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose 1. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Study: NCT00059930
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00059930
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00059930
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02260193
Drug: AKB-6548
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose 2. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Study: NCT04931433
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B will receive saline of similar volume and rate as Group A
Study: NCT01857921
Drug: Pravastatin 20mg/day for 12 months after randomization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with mono antiplatelet therapy with aspirin who had had received CABG previously fulfilling all enrollment criteria will be randomly assigned to the type of two groups. Randomization of statin therapy will be done 1:1 to one of two different groups on the web-based program:~1. Test group:~   * Atorvastatin 40 mg and trimetazidine MR 70 mg daily for 12 months after randomization~2. Control group:~   * Pravastatin 20mg daily for 12 months after randomization
Study: NCT02260193
Drug: AKB-6548
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose 3. Oral dose administered three times weekly for 16 weeks. Dose adjustment based on hemoglobin levels as defined in the protocol.
Study: NCT02815657
Drug: SP2086
Approvals — FDA: no, EMA: no, PMDA: no
Description: The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
Study: NCT01543399
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients of the placebo group will use placebo one a day for 30 days
Study: NCT01357161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to adavosertib, capsule, orally, BID for a total of 5 doses, starting on Day 1 of each 3-week cycle
Study: NCT02793817
Drug: KPI-121 1% Ophthalmic Suspension dosed BID
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02793817
Drug: Vehicle of KPI-121 Ophthalmic Suspension dosed BID
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04065074
Drug: FX006 32 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release 32 mg FX006 IA injection
Study: NCT03576755
Drug: Spironolactone 100mg
Normalized name: SPIRONOLACTONE 100MG TAB
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone capsules will be prepared from USP grade powder at a dose of 100 mg.
Study: NCT03576755
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules of the same color, mass, and appearance to the spironolactone capsules will be filled using microcrystalline cellulose powder.
Study: NCT02374814
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02839226
Drug: AR/101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02839226
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01291602
Drug: CAZ104
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Solution
Study: NCT01291602
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV saline
Study: NCT02305849
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT02305849
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tablet/capsule
Study: NCT04597125
Drug: NAH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive continuous NAH (either Abiraterone acetate plus prednisone/prednisolone \[AAP\] or enzalutamide) by mouth (per os) daily
Study: NCT04664972
Drug: Docetaxel +doxorubicin+ cyclophosphamide
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The control group was treated with TAC (docetaxel 75 mg / m2 + adriamycin 50 mg / m2 + cyclophosphamide 500 mg / m2) for 6 cycles, 21 days was a cycle.
Study: NCT01791049
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02782052
Drug: Nebulized Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL).
Study: NCT00620256
Drug: AL-37807 ophthalmic suspension, 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03783000
Drug: BI 425809 mixed with [C-14]-BI 425809
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment R
Study: NCT00245050
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm II: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral placebo 100 mg twice daily on days 1-28.
Study: NCT00245050
Drug: doxorubicin HCL liposome
Normalized name: DOXORUBICIN HCL LIPOSOME 2MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV, 40mg/m2
Study: NCT00152477
Drug: CDP791 10mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP791 20mg/mL vial CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
Study: NCT00152477
Drug: CDP791 20mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP791 20mg/kg CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
Study: NCT02160665
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle of Test product (G \& W Laboratories, Inc.)
Study: NCT02160665
Drug: Reference: Tazorac Cream, 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference: Tazorac (tazarotene) Cream, 0.05% (Allergan, Inc.)
Study: NCT02429219
Drug: Saline Irrigation with Ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline Irrigation with Ethanol (alcohol)
Study: NCT00825942
Drug: C-KAD Ophthalmic Solution
Normalized name: urea c-13 Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 drops applied daily for 180 days
Study: NCT01611688
Drug: NNC0215-0384
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.v.(intravenous) dose-escalation. Highest dose planned for i.v. administration is 10 mg/kg
Study: NCT01611688
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered i.v.(intravenous) or s.c. (subcutaneous, under the skin).
Study: NCT01611688
Drug: NNC0215-0384
Approvals — FDA: no, EMA: no, PMDA: no
Description: The s.c. (subcutaneous, under the skin) part will not start until at least two i.v. dose levels have been evaluated for safety and pharmacokinetics. Highest dose planned for s.c. administration is 4 mg/kg
Study: NCT00964041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by mouth, weekly, one hour before any assessments, each week for eight weeks.
Study: NCT04026009
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 2 doses (0.5 mL each) of Placebo, administered intramuscularly in the deltoid, at a 0, 1-month dose interval.
Study: NCT01581034
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of placebo will be taken. One capsule contains 403mg.
Study: NCT02182661
Drug: Ba253BINEB
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01059682
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally once daily
Study: NCT03086291
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 5-10mg/kg bid for 7 days and 14 days off treatment for 21 days
Study: NCT01083212
Drug: AZD1656
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose,oral tablet
Study: NCT01083212
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet bid on day 1-5
Study: NCT01541943
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, administered orally, 8 week
Study: NCT02529462
Drug: Treatment As Usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinicians treat psychiatric patients in a naturalistic way, following their routine procedures, without access to the pharmacogenetic information provided by the NEUROPHARMAGEN test
Study: NCT02973295
Drug: Silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules contains 100 mg of silymarin
Study: NCT02340208
Drug: L-DOS47
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: A treatment cycle will be 21 days with patients receiving L-DOS47 on cycle Days 1 and 8.
Study: NCT03482648
Drug: BBT-401-1S, Single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of BBT-401-1S, 7 dose levels, oral capsule
Study: NCT03482648
Drug: BBT-401-1S, Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of BBT-401-1S, 7 days, 3 dose levels, oral capsule
Study: NCT03482648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to BBT-401-1S, oral capsule
Study: NCT01979666
Drug: placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: control group patients will get a placebo patch
Study: NCT03878381
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be a formula with no active ingredients
Study: NCT04136327
Drug: GLPG1972 film-coated tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose of GLPG1972
Study: NCT04136327
Drug: [14C]-GLPG1972 solution for infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: a 15-minute IV infusion \[14C\]-GLPG1972
Study: NCT04136327
Drug: [14C]-GLPG1972 oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose of \[14C\]-GLPG1972
Study: NCT01180894
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03170115
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemoradiotherapy with capecitabine and placebo Placebo daily during chemoradiotherapy
Study: NCT06362473
Drug: Lipid-lowering treatments
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04486430
Drug: Neu2000KWL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1st infusion of 500mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 250 mg at intervals of 12 hours
Study: NCT04486430
Drug: Neu2000KWL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1st infusion of 750mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
Study: NCT04486430
Drug: Neu2000KWL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1st infusion of 1500mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
Study: NCT04486430
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1st infusion of the same volume of saline in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of the same volume of saline at intervals of 12 hours